What is NRX Pharmaceuticals Inc (NRXP) Price Targets?

NRX Pharmaceuticals Inc (NASDAQ:NRXP) saw a downside of -1.50% to close Friday at $0.26 after subtracting $0.0 on the day. The 5-day average trading volume is 743,980 shares of the company’s common stock. It has gained $0.2800 in the past week and touched a new high 1 time within the past 5 days. An average of 2,534,970 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,666,556.

NRXP’s 1-month performance is -9.70% or -$0.0455 on its low of $0.2210 reached on 09/08/23. The company’s shares have touched a 52-week low of $0.22 and high of $1.54, with the stock’s rally to the 52-week high happening on 01/13/23. YTD, NRXP has lost -76.94% or -$0.8540 and has reached a new high 4 times. However, the current price is down -83.38% from the 52-week high price.

Insider Transactions

NRXP stock investors last saw insider trading activity on Aug 30.Javitt Jonathan C (Director) most recently sold 400,000 shares at $1.00 per share on Dec 07. This transaction cost the insider $400,000. 10% Owner, Javitt Daniel C., sold 8,441 shares at a price of $1.50 on Nov 30. Then, on Nov 29, 10% Owner Javitt Daniel C. sold 13,730 shares at a price of $1.50 per share. This transaction amounted to $20,651.

Valuation Metrics

NRXP stock has a beta of 0.87.

NRX Pharmaceuticals Inc’s quick ratio for the period ended June 29 was 0.87, with the current ratio over the same period at 0.87.

Earnings Surprise

For the quarterly period ending June 29 this year, Net income grew 19.95% to -$8.72 million, while revenue of -$11.04 million was -26.61% off the previous quarter. Analysts expected NRXP to announce -$0.14 per share in earnings in its latest quarter, but it posted -$0.12, representing a 14.30% surprise. NRXP stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 22.62 million, with total debt at $12.69 million. Shareholders hold equity totaling $81.7 million.

Let’s look briefly at NRX Pharmaceuticals Inc (NRXP) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 September was 42.60% to suggest the stock is trending Neutral, with historical volatility in this time period at 82.01%.

The stock’s 5-day moving average is $0.2546, reflecting a -10.18% or -$0.0290 change from its current price. NRXP is currently trading -24.71% above its 20-day SMA, -55.17% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -35.84% and SMA200 by-81.71%.

Stochastic %K and %D was 39.36% and 34.17% and the average true range (ATR) pointed at 0.0269. The RSI (14) points at 41.16%, while the 14-day stochastic is at 40.46% with the period’s ATR at 0.0301. The stock’s 9-day MACD Oscillator is pointing at -0.0031 and -0.0034 on the 14-day charts.

Analyst Ratings

Analysts offering their rating for NRXP stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate NRXP as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.

What is NRXP’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $2.00 and a high of $5.25, with their median price target at $3.63. Looking at these predictions, the average price target given by analysts is for NRX Pharmaceuticals Inc (NRXP) stock is $3.63.

Most Popular

Related Posts